Cancer Treatment News and Research

RSS

Results from Phase I trial of Bryan Oncor's targeted radiopharmaceutical therapy reported

Bryan Oncor reports the results of a Phase I trial of its targeted radiopharmaceutical therapy using Re-88 P2045, a radiolabeled synthetic peptide, for the treatment of advanced lung cancer.

21 Dec 2009

Clarient announces acquisition of Applied Genomics

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it has acquired privately held, Huntsville, AL-based Applied Genomics, Inc. (AGI) in an all-stock merger valued at up to $17.6 million, if all conditions and milestones set forth in the merger agreement are successfully met.

21 Dec 2009

Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy

Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today that they have entered into a global license and collaboration agreement to develop and commercialize OGX-011, as well as an agreement to purchase shares in OncoGenex. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance.

21 Dec 2009

Soligenix commences SGX201 Phase 1/2 clinical trial for acute radiation enteritis prevention

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has initiated a Phase 1/2 clinical trial evaluating SGX201, a time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP), for the prevention of acute radiation enteritis.

21 Dec 2009

Medical physicists converge at ProCure TDC for training in physics of protons and proton therapy

Medical physicists from around the world converged at the ProCure Training and Development Center (TDC) last week for intense training in the physics of protons and proton therapy, an alternative to X-ray radiation for cancer treatment that spares healthy tissue and results in far fewer short- and long-term treatment side effects.

19 Dec 2009

Ontario surpasses federal target for radiation therapy

For the past 12 months, Ontario has surpassed the federal target for radiation therapy wait times, demonstrating that the province has continued to improve access to this important cancer treatment.

19 Dec 2009

John Theurer Cancer Center presents over 20 research updates and trial results at the 2009 ASH meeting

Doctors and researchers from the John Theurer Cancer Center at Hackensack University Medical Center recently presented research updates and clinical trial results of more than 20 innovative studies at the American Society of Hematology (ASH) annual meeting from December 5-8, 2009.

18 Dec 2009

Tackle Cancer Foundation calls attention to REVLIMID for myeloma patients

The TACKLE CANCER FOUNDATION wants to call attention to important news for patients with the blood cancer multiple myeloma. A new study shows patients benefit from daily medical treatments to keep their cancer in check after they have had a stem cell (bone marrow) transplant. The current standard of care is to give patients the transplant and then hold off on additional treatment until they relapse. The new study shows continuous treatment with the oral drug REVLIMID following the transplant significantly prolongs remission, increasing time to disease progression.

18 Dec 2009

Cost of Avastin a deterrent for non-small-cell lung cancer treatment

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the cost of Roche/Chugai's Avastin, followed by concerns about its efficacy and side-effect profile, are cited most frequently by surveyed oncologists as the factors preventing their use of Avastin for non-small-cell lung cancer treatment in Germany, France, Italy, Spain and the United Kingdom.

18 Dec 2009

NiTi Surgical Solutions' ColonRing used for the first time in a colorectal surgery in China

NiTi™ Surgical Solutions, an innovative surgical device company, today announced that its ColonRing™, the first major advance in closure for gastrointestinal surgery in more than 30 years, has been used for the first time in a colorectal surgery in China. The ColonRing anastomosis device was launched in the United States in May 2008 and has been successfully applied in thousands of patients.

18 Dec 2009

FDA advisory committee votes against approval of Tarceva for lung cancer treatment

Yesterday, an advisory committee to the Food and Drug Administration voted against the approval of Tarceva(R) (erlotinib) as maintenance treatment for advanced lung cancer patients.

18 Dec 2009

Brachytherapy for lung cancer

A 58-year-old man who lives in Corona, Queens came to the emergency room of New York Hospital Queens (NYHQ) with extreme pain and tingling in his left arm. Although he did not realize it at the time, he had lung cancer. Recently, he made medical history as the first patient in the United States to be treated for lung cancer through the use of radioactive pellets placed directly in the tumor, and today his recovery is going well. Known as brachytherapy, this treatment approach is commonly used to treat prostate cancer.

18 Dec 2009

New study to examine physical activity and dietary behavior of colorectal cancer patients

In an effort to build the groundwork for future research on health promotion among individuals with colorectal and other cancers, a team of investigators at The Cancer Institute of New Jersey (CINJ) has launched a new study examining patterns in physical activity and eating habits of colorectal cancer patients who have recently finished treatment. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

18 Dec 2009

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

David Allan, Chairman and CEO of YM BioSciences Inc. and Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced the signing of an agreement under which Therapure Biopharma will provide fill and finish services for nimotuzumab, the humanized monoclonal antibody licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of Molecular Immunology (CIM).

17 Dec 2009

Pure populations of immature cells that enable male reproduction isolated and transplanted

Reproductive researchers from the University of Pennsylvania and The Children's Hospital of Philadelphia have succeeded in isolating and transplanting pure populations of the immature cells that enable male reproduction in two species-human spermatogonia and mouse gonocytes. These germline stem cells, taken from testis biopsies, demonstrated viability following transplantation to mouse testes within a controlled laboratory setting.

15 Dec 2009

Nanoparticle could allow diagnosis and treatment in one visit

Researchers at Rice University and Baylor College of Medicine (BCM) have created a single nanoparticle that can be tracked in real time with MRI as it homes in on cancer cells, tags them with a fluorescent dye and kills them with heat.

15 Dec 2009

Study finds racial disparities in breast cancer care

Black women are less likely than white women to receive radiation therapy after a lumpectomy, the standard of care for early stage breast cancer, according to a new study by researchers at The University of Texas M. D. Anderson Cancer Center.

14 Dec 2009

Cell-enriched breast reconstruction procedure improves breast deformity in lumpectomy patients

Interim results from a European clinical trial, RESTORE 2, demonstrate that cell-enriched breast reconstruction achieved a high rate of patient and physician satisfaction and improvements in overall breast deformity in lumpectomy patients.

14 Dec 2009

African American women with breast cancer receive no follow-up care after lumpectomy, shows study

A new study finds many breast cancer patients - particularly African American women - do not receive recommended radiation treatments after undergoing a lumpectomy.

14 Dec 2009

Combination of Herceptin and chemotherapy improves treatment for women with HER2+ breast cancer

Using Herceptin with chemotherapy, instead of after, clearly improves treatment of women with HER2+ breast cancer, and should be the new standard of care, says a Mayo Clinic researcher who led what is regarded to be a key clinical trial determining the best use of Herceptin.

14 Dec 2009

Cancer Treatment News and Research

Results from Phase I trial of Bryan Oncor's targeted radiopharmaceutical therapy reported

Clarient announces acquisition of Applied Genomics

Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy

Soligenix commences SGX201 Phase 1/2 clinical trial for acute radiation enteritis prevention

Medical physicists converge at ProCure TDC for training in physics of protons and proton therapy

Ontario surpasses federal target for radiation therapy

John Theurer Cancer Center presents over 20 research updates and trial results at the 2009 ASH meeting

Tackle Cancer Foundation calls attention to REVLIMID for myeloma patients

Cost of Avastin a deterrent for non-small-cell lung cancer treatment

NiTi Surgical Solutions' ColonRing used for the first time in a colorectal surgery in China

FDA advisory committee votes against approval of Tarceva for lung cancer treatment

Brachytherapy for lung cancer

New study to examine physical activity and dietary behavior of colorectal cancer patients

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

Pure populations of immature cells that enable male reproduction isolated and transplanted

Nanoparticle could allow diagnosis and treatment in one visit

Study finds racial disparities in breast cancer care

Cell-enriched breast reconstruction procedure improves breast deformity in lumpectomy patients

African American women with breast cancer receive no follow-up care after lumpectomy, shows study

Combination of Herceptin and chemotherapy improves treatment for women with HER2+ breast cancer

Cancer Research eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News